Navigation Links
Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals, Inc. (Amex: PRW), a company "Advancing Drugs Through Glycoscience(R)", today updated the progress of its Phase II clinical trial for first-line treatment of metastatic, unresectable colorectal cancer patients who are unable to tolerate irinotecan and/or oxaliplatin, and its Phase II clinical trial for first-line treatment of biliary cancer patients. Treatment for both indications may represent orphan drug status for DAVANAT(R), the Company's target delivery compound. In addition, the Company plans to submit the manufacturing data requested by the FDA this year for DAVANAT(R) 505 (b)(2) filings as a functional excipient.

Phase II, First Line Treatment, Colorectal Cancer Trial

To date, eight patients have been dosed with DAVANAT(R) in combination with 5-FU, Avastin(R) and leucovorin. Two patients have tumor shrinkage of greater than 30%, a partial response according to Response Evaluation Criteria for Solid Tumors (RECIST). Five patients have stable disease for up to seven months and one had non-drug related progressive disease. Patients experienced no increase in drug-related toxicity and reduced side effects with increased exposure to 5-FU and AVASTIN(R). The Simon two-stage designed study is an open-label, multi-center trial. The primary objectives of the trial are tumor shrinkage and progression-free survival. Six sites are actively recruiting patients. Additional sites are expected to be active shortly. Nine of 25 (36%) end-stage colorectal cancer patients from Phase I/II trials were stabilized from 2 to 8 months.

Phase II, First Line Treatment, Biliary Cancer Trial

To date, seven patients have been dosed with DAVANAT(R) in combination with 5-FU. One patient has tumor shrinkage of greater than 30%, a partial response according to RECIST. Five patients have stable disease for up to five months and one had non-drug related
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. NCCN Updates Esophageal and Gastric Cancer Guidelines
5. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
6. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
10. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
11. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
Post Your Comments:
(Date:5/16/2008)...ng Will Further Demonstrate, the Strength of VEL..., CAMBRIDGE, Mass., May 16 /- Millen... today announced that new data from VELCADE,clinic...8 American Society,of Clinical Oncology (ASCO) Ann... 2008. The data will highlight the significant eff...
(Date:5/16/2008)...er thought leaders -, SAN FRANCISCO, May 16 /PRNe...trusted resource for clinical trial management sys...us academic medical centers, research,institutions...eting in San,Francisco. The Velos eResearch system...y manage thousands of clinical trials., Over 140 ...
(Date:5/16/2008)...ing that TYKERB and trastuzumab together resulted,...n-free survival (PFS), -- Combining TYKERB and tr... the HER2 receptor may create a more complete HER2...RB alone despite patients,previous treatment with...LONDON and PHILADELPHIA, May 16 /PRNewswire-USNews...
(Date:5/16/2008)...ex, LLC announced today that,its licensing collabo...(LabCorp), has commercially launched a new gene me...uses the biological specificity of ,DNA,methylatio...f the gene,GST-Pi. Methylation is a modification o...developing the methylation markers in this tissue ...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Cardiac Science to Present at the 18th Annual CIBC World Markets Healthcare Conference 4889 1Cardiac Science to Present at the 18th Annual CIBC World Markets Healthcare Conference 4889 2Nastech Announces Third Quarter 2007 Financial Results 1573 1Nastech Announces Third Quarter 2007 Financial Results 1573 2Nastech Announces Third Quarter 2007 Financial Results 1573 3Nastech Announces Third Quarter 2007 Financial Results 1573 4Nastech Announces Third Quarter 2007 Financial Results 1573 5Nastech Announces Third Quarter 2007 Financial Results 1573 6Certain Seizure Patients Need Emergency CT Scan 4887 1Certain Seizure Patients Need Emergency CT Scan 4887 2Agendia BV Appoints Clinical and Scientific Advisory Board 1570 1Agendia BV Appoints Clinical and Scientific Advisory Board 1570 2
... Infants Infected by Members of Their Own Househol... A new study,released today in the April issue of ... transmission of pertussis -- commonly,known as wh...the,source for 71 to 82 percent of cases among inf...) The study demonstrates the,importance of vaccina...
...ss.--(BUSINESS WIRE)--Mar 27, 2007 - Interleukin,G...University of,California San Diego today reported ...ng that associations between coronary artery,disea...d Lp(a),levels appear to be dependent on pro-infla...., In a presentation titled "The Influence of Oxid...
Other Medicine Technology:New Study Confirms Role for Pertussis Immunization of Entire Family,in Reducing Infant Pertussis 2New Study Confirms Role for Pertussis Immunization of Entire Family,in Reducing Infant Pertussis 3New Study Confirms Role for Pertussis Immunization of Entire Family,in Reducing Infant Pertussis 4New Study Confirms Role for Pertussis Immunization of Entire Family,in Reducing Infant Pertussis 5New Study Confirms Role for Pertussis Immunization of Entire Family,in Reducing Infant Pertussis 6ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 2ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 3
(Date:5/16/2008)...n Society of Clinical Oncology meeting in Chicago ... about 25 percent of patients with colon cancer an...orectal cancers will be staged. , This new stu...ulation-based statistic registries from 1992 to 20...outcomes of patients with positive nodes (Stage II...
(Date:5/16/2008)...ewswire/- "Huh, what did you,say?" is a phrase bei...children. More than 30 million Americans, that is ...and the numbers are growing at a dramatic rate.,Th...ome form of hearing,loss. An effort to bring more ...hat led Kathlyn Maguire, who has profound hearing ...
(Date:5/16/2008)... HIV Vaccine Awareness Day, May,18, WASHINGTON, M...into the,AIDS epidemic, someone is newly infected ...ay 18, HIV Vaccine Awareness Day, AIDS Action, one...te of Allergy and Infectious,Disease (NIAID) HIV V...ne,to help end the AIDS epidemic by participating ...
(Date:5/16/2008)...e/ -- As tropical storms,continue to batter the af...yclone Nargis are vulnerable to diseases and other...ance, as exposure to the foul weather and,malnutri... "The people living in these conditions urgently ...et back on their feet," said David Meltzer,senior...
Breaking Medicine News(10 mins):Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Myanmar Cyclone Survivors Face New Challenges 2
...ly thought to be just 'empty calories', actually h...entific and Industrial Research Organisation (CSIR...h could be as important as fibre in the fight agai...ave noted that people in Africa, Japan and China h...
...establish whether people who exercise can improve ...ll! Consensus statements published by th...that people who exercise improve their health.// B...w much health-improvement pay-off will result from...
...m, sponsored by the National Institutes of Health,... 30 minutes per day reduced their risk of diabetes...t risk of developing type 2 diabetes can sharply r...en of diet and exercise, according to data from th...
...cts, such as tomato sauce and ketchup, have long b...ers, especially prostate cancer, but the reason fo...ls have suggested that lycopene, which is found in...nt nutrients may be effective in preventing prosta...
Other Medicine News:Health News:How much can exercise improve health? 2Health News:Protective effects of tomatoes in prostate cancer 2
8 mm diameter nylon handpiece; 100 mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper.
4-Strand Basket Retriever was developed to facilitate recovery of foreign objects from within the neuro, peripheral, and cardiovasculature, the In-Time Retrieval Device features an integrated corewir
Novalis, BrainLAB's dedicated system for non-invasive stereotactic radiosurgery and radiotherapy (SRS/SRT), represents cutting-edge technology for highly precise treatments of brain as well as head &
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments.
Medicine Products: